CytomX Therapeutics’ consensus price target has increased notably, driven by a substantially higher expected P/E despite a decline in net profit margin, resulting in a revised fair value of $5.75 per share.
What's in the News
- First patient dosed with CX-801 in combination with KEYTRUDA in a Phase 1 dose escalation study for metastatic melanoma.
- CX-801 is a dually masked interferon alpha-2b PROBODY cytokine designed to improve the safety and efficacy of interferon alpha-2b in oncology.
- CX-2051, discovered with ImmunoGen, targets EpCAM-expressing epithelial cancers, including colorectal cancer.
- CytomX has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna.
- Q2 2025 results expected to be reported on August 6, 2025.
Valuation Changes
Summary of Valuation Changes for CytomX Therapeutics
- The Consensus Analyst Price Target has significantly risen from $5.04 to $5.75.
- The Future P/E for CytomX Therapeutics has significantly risen from 78.87x to 293.52x.
- The Net Profit Margin for CytomX Therapeutics has significantly fallen from 15.87% to 13.95%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.